In small clinical studies and collections of patient cases with kidney diseases including WT1 mutation-associated glomerular disease, membranous nephropathy, and Alport nephropathy, CsA or FK506 can improve the course of the kidney disease (Charbit et al., 2007; Waldman et al., 2007; Bensman and Niaudet, 2010; Chiba and Inoue, 2019). This evidence concerns the gene WT1 and kidney disorder.